In 2026, sales are expected to grow by a high single-digit percentage at CER. Business EPS at CER is expected to grow slightly faster than sales before share buyback, delivering profitable growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Regeneron, Sanofi: FDA approves Dupixent for treatment of CSU in ages 2-11
- SNY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Sanofi downgraded to Neutral from Outperform at BNP Paribas
- Sanofi’s Real‑World Teplizumab Study Targets Early Type 1 Diabetes Insights for Investors
- Sanofi says COVID-19 vaccine showed better tolerability than Moderna’s